What Is Vilon?
Published Oct 15, 2026 · 14 minute read
Vilon is a synthetic peptide made of only two amino acids, lysine and glutamic acid. Vladimir Khavinson’s institute in St. Petersburg developed it and promotes it as a “bioregulator” for the thymus, the gland where T cells mature. It is not an approved drug in the US, and no randomized, placebo-controlled human trial has been published; the most notable finding in its developers’ own work is that it increased breast tumors in a cancer-prone mouse strain.
Key Takeaways
- Vilon is a synthetic dipeptide, lysine joined to glutamic acid, developed by Vladimir Khavinson's institute in St. Petersburg and promoted as a thymus bioregulator.
- No randomized, placebo-controlled human trial has been published. The human reports are small Russian studies whose abstracts omit patient numbers, doses and control groups.
- Almost all research comes from one network of authors, and no independent group has replicated the findings.
- In cancer-prone HER-2/neu mice, vilon increased breast tumors; in mice with lung tumors, combining it with cyclophosphamide shortened survival.
- Vilon is not an FDA-approved drug, has no published half-life or toxicology data, and has never been studied alongside GLP-1 medicines.
Vilon belongs to the same family of short Russian peptides as epitalon, pinealon and cartalax. Online it is sold for immunity and healthy aging. The supporting research is almost entirely cell-culture and rodent work from one group of authors, plus a few small clinical reports that omit basic details such as how many patients took part.
That makes vilon a useful case for reading peptide claims carefully. A long reference list can still describe a narrow and largely unreplicated evidence base.
| Vilon at a glance | What to know |
|---|---|
| Other names | Peptide vilon; chemical name L-lysyl-L-glutamic acid |
| Class | Synthetic dipeptide (two amino acids) in the Khavinson “peptide bioregulator” family |
| Claimed role | Thymus-mimicking immune regulator and geroprotector, meaning anti-aging agent |
| US status | Not an FDA-approved drug |
| WADA | Not named on the 2026 list; covered in principle by class S0 for unapproved substances |
| Route in studies | Subcutaneous injection in the rodent studies that state a route; one rat study gave it by mouth |
| Half-life | Unknown; no pharmacokinetic study in people or animals has been published |
| Human data | Three small Russian clinical abstracts (type 1 diabetes, older adults with colorectal cancer); no described randomization or placebo |
| Main evidence gap | No controlled human trial and no independent replication |
1. What is vilon, and where does it come from?
PubChem’s compound record lists vilon as a synonym for the dipeptide formed when lysine is linked to glutamic acid. That makes it one of the smallest molecules sold under the bioregulator label. Its developers call it a “thymomimetic,” a substance intended to imitate the actions of thymus hormones.
The group’s own accounts of its origin are not consistent. Morozov and Khavinson’s 1997 review describes it as a newly synthesized immunomodulating dipeptide. A 2023 paper by Linkova and colleagues instead calls it one of the active substances in thymalin, a calf thymus extract, although that study used modeling and cell culture and does not report measuring vilon in the extract.
Vilon should not be confused with thymulin, a separate nine-amino-acid hormone made by the thymus itself, or with thymosin alpha-1. Each of these molecules has its own, unrelated body of research.
2. How is vilon supposed to work?
No study has shown how vilon acts in a living person. The developers propose that very short peptides slip into cells, reach the nucleus and attach to DNA, where they help switch particular genes on or off. Most of the support for that idea is computational.
- Docking models. Computer simulations predicted that the dipeptide fits short DNA stretches in the control regions of genes coding for CD5 and IL-2, two immune signaling proteins (Khavinson and colleagues, 2013) and of the aging-linked genes SIRT1, PARP1 and PARP2 (a 2023 follow-up).
- Whole peptide versus its building blocks. In rat spleen tissue cultures, the intact dipeptide stimulated cell growth while a simple mix of its two amino acids suppressed it (Khavinson and colleagues, 2015).
- Ultra-low concentrations. A 2003 Russian paper reported a second activity peak on thymus cells at vanishingly small concentrations and proposed that water carries the signal. That explanation sits outside accepted pharmacology and has not been independently tested.
The group has acknowledged the gap. In a 2016 review, its authors wrote that the molecular mechanism of gene regulation by short peptides remains unclear. A docking score predicts that binding is possible; it does not show that binding happens in a living cell, let alone that it changes immune function.
3. What human studies of vilon exist?
The human record is thin. None of the abstracts below states how many patients were treated, what dose they received, or whether a comparison group was randomized or blinded.
| Report | Population | What the authors reported |
|---|---|---|
| Kuznik et al., 2006 | People of various ages with unstable type 1 diabetes | Added to standard care, vilon reduced or removed signs of chronic abnormal clotting activity; weaker effect in older patients with severe disease |
| Kuznik et al., 2007 | Older adults with type 1 diabetes | Higher antithrombin III and protein C, two natural anticoagulants; a lower insulin requirement “in most cases”; shifts in immune cell counts |
| Ias’kevich et al., 2005 | Older patients with stage III colon or rectal cancer | Called a pioneering experience with preliminary results; recommends vilon for two-year survival without reporting survival figures |
A 2013 review by Khavinson and colleagues summarizes the group’s clinical experience with several bioregulators. Its abstract gives no trial designs, patient counts or vilon-specific outcomes.
The one human-tissue experiment often cited is not a treatment study. Lezhava and colleagues exposed white blood cells from donors aged 75 to 88 to vilon in culture and reported loosening of tightly packed chromatin, the DNA-protein material in chromosomes.
Who did the research?
Nearly every vilon paper lists Khavinson or staff of his institute as authors. Even the studies run in Georgia and Italy include him as a co-author (Lezhava et al., 2004; Avolio et al., 2022). No independent replication was found, and many papers are short Russian articles available only as abstracts.
4. What did cell and animal studies find?
Cell cultures
These experiments measured gene activity, signaling molecules or staining in cells grown in a dish. They are laboratory findings, not evidence of better immunity in people.
| Study | Cells | Reported finding |
|---|---|---|
| Khavinson et al., 2002 | Mouse thymus cells | Strongest growth-boosting effect of three peptides tested, ahead of epitalon |
| Avolio et al., 2022 | Human leukemia-derived monocyte line | Lower TNF and IL-6 release after bacterial endotoxin, and less cell adhesion |
| Linkova et al., 2023 | Blood immune cells from four donors | Inflammatory signals IL-1β, IL-6 and TNF-α fell 1.4- to 6.0-fold after endotoxin |
| Khavinson et al., 2023 | Human stem cells undergoing replicative aging | SIRT1 gene expression up 6-fold and protein up 8.2-fold in younger cells |
| Ashapkin et al., 2020 | Human fetal bone-marrow stem cells | IGF1 gene expression up 3.5- to 5.6-fold alongside other short peptides; NF-κB also raised |
| Fridman et al., 2020 | Aging human skin fibroblasts | Lower IL-1, NF-κB and TGF-β; higher sirtuin-6 |
| Ivko et al., 2020 | Aging human thymus cells | Mitochondrial staining up 1.5-fold; a ribosomal protein down 15% |
Not all results pointed the same way. In a 2008 Russian study, vilon and three sister peptides did not act as antioxidants on their own. In nerve cells they actually pushed resting levels of reactive oxygen species higher, even as fewer cells died.
Lifespan in mice
Lifespan extension is the claim most often repeated online, and the two mouse reports do not line up neatly.
| Study | Design | Result |
|---|---|---|
| Khavinson et al., 2000 | Female CBA mice injected subcutaneously starting at six months old | Reported longer lifespan, more activity and fewer spontaneous tumors; the abstract gives no numbers |
| Anisimov et al., 2001 | Female CBA mice, 0.1 µg per mouse for five days each month until death, compared with saline or epitalon | More physical activity and fewer spontaneous lung adenomas with vilon; the significant survival gain (mean +5.3%) was reported for epitalon only |
Other rodent studies
In rats exposed to 6 Gy of whole-body gamma radiation, vilon was reported to stimulate thymus cell growth and intestinal stem cell activity (Khavinson et al., 2001). In old male rats with one testis removed, 50 µg per rat was said to activate sexual function, with changes in LH, prolactin and ACTH (Kudriavtseva et al., 2006). Given by mouth to rats, it altered several digestive enzymes (Khavinson et al., 2001).
These hormone changes were measured in rats only. They do not tell anyone tracking testosterone, LH or fertility markers what vilon would do in a person, because no human study has measured those outcomes.
5. Can vilon increase cancer risk?
The direction of vilon’s effect on tumors depended on the model, and one model showed clear harm.
| Model | Reported result |
|---|---|
| HER-2/neu transgenic mice, which develop breast cancer on their own; 1 µg per mouse on five days of each month (Anisimov et al., 2002) | Vilon significantly raised breast cancer incidence and tumor count and brought tumors on sooner than saline; epitalon reduced tumor number and size |
| HER-2/neu mice, companion Russian-language paper (Alimova et al., 2002) | Two or more tumors in 95% of vilon mice vs 75% on saline and 56% on epitalon; lung metastases 2.6 times as frequent with vilon as with epitalon |
| Rats exposed to a chemical that causes bladder cancer (Pliss et al., 2001) | 56% of vilon-treated rats developed bladder tumors, compared with 75.5% of untreated controls |
| Mice exposed to a colon cancer-causing chemical; 10 µg/kg (Pliss et al., 2005) | 14.3% of surviving vilon-treated mice had tumors, against 60% of controls |
| Mice with transplanted lung carcinoma (Barykina et al., 2003) | 1 mg/kg alone improved survival; given together with cyclophosphamide, it shortened survival |
Some studies reported fewer chemically induced tumors, so the results cannot be summarized as simply protective or harmful. The breast cancer finding matters because it came from the developers’ own laboratory and was statistically significant. Separately, stem cell work found vilon raised IGF1, a growth-promoting gene, and NF-κB, a master switch for inflammation. No one has examined whether it changes cancer risk in humans.
6. Is vilon legal or FDA-approved?
Vilon is not an approved drug in the US, and no FDA or EMA approval was found. It did not appear on the FDA’s list of bulk substances that may present significant safety risks in compounding in its April 2026 version, although that page does name epitalon. Not being listed is not a safety review.
For athletes, vilon is not named on the 2026 WADA Prohibited List. Class S0 bans at all times any pharmacological substance without current government approval for human therapeutic use, and no vilon-specific WADA ruling was found.
7. Is there a vilon dose or known half-life?
No human dose has been established. The only doses in the cited abstracts are from rodents: 0.1 to 1 µg per mouse injected subcutaneously on five days of each month, 10 µg/kg and 1 mg/kg in mice, and 50 µg per rat. Animal doses cannot be scaled into a human regimen, and finding a safe or effective amount was never the aim of any of them.
Vilon’s half-life is unknown. No published study has measured its absorption, distribution or elimination in any species. The closest work is a 2023 computer modeling study which predicted that it and other ultrashort peptides might be carried into cells by amino-acid and peptide transporters (the LAT1, LAT2 and PEPT1 proteins). Whether intact vilon survives digestion, or how quickly an injected dose is cleared from the blood, remains unreported.
That limits what a half-life chart can show. Any curve would be built on an assumed number rather than a measured one.
8. Side effects, interactions and GLP-1 medicines
Nobody has run a formal safety study of vilon in humans. Standard animal toxicology work, such as acute, repeat-dose, reproductive and genetic-damage testing, has not been published either, and no study has looked at how the response changes with dose. Whether it is safe during pregnancy or breastfeeding, in children, or for someone with cancer, an autoimmune condition, or kidney or liver problems has simply never been examined. The 2000 lifespan study said long-term use caused no unfavorable effects in mice, which is one animal report rather than a human safety record.
Interactions
The only interaction signal is from rodents: tumor-bearing mice that received vilon together with cyclophosphamide, a chemotherapy drug, died sooner, and the authors advised against combining them. No human interaction data exist for any drug.
Vilon with semaglutide, tirzepatide or insulin
No study has tested vilon with semaglutide, tirzepatide or any other GLP-1 medicine. There is also no evidence that it affects appetite, body weight or muscle preservation during weight loss.
One point is relevant to people on glucose-lowering treatment. In the 2007 type 1 diabetes report, the authors described a lower insulin requirement in most patients. That uncontrolled observation does not establish an effect, but it is a reason not to assume vilon is neutral for anyone whose insulin or other glucose-lowering doses are being adjusted.
Product quality
Whatever is sold online under the vilon name falls outside US drug regulation, so no regulator verifies that a capsule or vial contains the stated peptide at the stated amount, free of contaminants, or sterile if meant for injection. For related research peptides such as epitalon, the FDA has flagged the risk that impurities or clumped peptide in injectables could provoke immune reactions.
9. What can you actually measure or track?
Vilon’s claimed benefits, such as “thymus support” or slower aging, have no validated blood marker in people. Routine immune cell counts, inflammatory markers or a fitness score would not show whether vilon did anything, because no controlled study has linked it to changes in those measures.
What a log can do is keep the timeline straight. Recording the product name and lot, dates, other medicines, glucose readings if you have diabetes, and any symptoms makes it easier to discuss changes with a clinician. If several peptides are started together, no log can tell which one caused an effect. The tracking guide covers how to keep those records usable.
The evidence that would change this picture is a randomized, placebo-controlled human trial with a defined product, measured blood levels, meaningful clinical outcomes and independent investigators. None has been published.
10. Vilon FAQ
What is vilon used for?
Sellers market vilon for immunity and anti-aging. Its developers describe it as a thymus bioregulator. Those uses rest on cell, rodent and small uncontrolled Russian clinical reports, not on controlled human trials.
Is vilon legal or FDA-approved?
Vilon is not an FDA-approved drug, and no FDA or EMA approval was found. It is not named on the 2026 WADA Prohibited List, but WADA's S0 class bans substances without government approval for human therapeutic use.
What are the side effects of vilon?
No study has measured side-effect rates in people. The main safety concern comes from mice: vilon increased breast cancer in a cancer-prone strain and shortened survival when given with a chemotherapy drug.
How long does vilon stay in your system?
Nobody knows. No published study has measured its absorption, half-life or elimination in people or animals, so any half-life quoted online lacks a measured basis.
Is there a recommended vilon dose?
No human dose has been validated. The only doses reported in the cited abstracts come from mouse and rat experiments, and those cannot be converted into a human dose.
Can vilon be used with semaglutide or tirzepatide?
No study has tested vilon alongside semaglutide, tirzepatide or any GLP-1 medicine. Interaction, safety and added-benefit data do not exist.
Is vilon the same as thymalin or thymulin?
No. Thymalin is a calf thymus extract that vilon's developers link it to, and thymulin is a separate nine-amino-acid thymus hormone. Each has its own research.
Does vilon extend lifespan?
Not in people, where it has never been tested for that. In a 2001 study of female mice, the reported significant survival gain was for epitalon, not vilon.
11. Sources
References used for this article
- PubChem: Compound summary for vilon (CID 7010502)
- Morozov and Khavinson (1997): Natural and synthetic thymic peptides for immune dysfunction
- Linkova et al. (2023): Thymalin dipeptides, cytokines and gene expression in immune cells
- Khavinson et al. (2013): Docking model of short peptides and gene promoter sites
- Khavinson et al. (2023): Vilon peptide and SIRT1, PARP1, PARP2 in aging stem cells
- Khavinson et al. (2015): Role of the peptide bond in short-peptide activity
- Grigor'ev et al. (2003): Ultra-low-dose peptide activity and the water medium
- Khavinson et al. (2016): Short peptides and gene expression review
- Khavinson et al. (2023): Modeling short-peptide transport via LAT and PEPT transporters
- FDA (2026): Bulk drug substances that may present significant safety risks
- WADA: 2026 Prohibited List
- Lezhava et al. (2004): Vilon and chromatin in cultured lymphocytes from older donors
- Avolio et al. (2022): Khavinson peptides in THP-1 monocyte cells
- Kuznik et al. (2006): Vilon and blood coagulation in type 1 diabetes
- Kuznik et al. (2007): Vilon, immune status and hemostasis in diabetes
- Ias'kevich et al. (2005): Peptide bioregulator in elderly colorectal cancer patients
- Khavinson et al. (2013): Peptide bioregulators as geroprotectors, clinical results review
- Khavinson et al. (2002): Short peptides and thymocyte blast transformation
- Ashapkin et al. (2020): Short peptides and gene expression in aging stem cell cultures
- Fridman et al. (2020): Vilon and AED peptides in aging skin fibroblasts
- Ivko et al. (2020): AEDG and vilon peptides in aging pineal and thymus cells
- Kozina et al. (2008): Regulatory peptides in in-vitro model experiments
- Khavinson et al. (2000): Vilon, biological age and lifespan in mice
- Anisimov et al. (2001): Thymic and pineal peptides, survival and tumors in CBA mice
- Anisimov et al. (2002): Epitalon, vilon and mammary tumors in HER-2/neu mice
- Alimova et al. (2002): Epitalon and vilon in transgenic erbB-2/neu mice
- Pliss et al. (2001): Vilon and induced bladder tumors in rats
- Pliss et al. (2005): Vilon and dimethylhydrazine-induced tumors in mice
- Barykina et al. (2003): Vilon combined with cyclophosphamide in tumor-bearing rodents
- Khavinson et al. (2001): Vilon and epitalon in radiosensitive organs of irradiated rats
- Kudriavtseva et al. (2006): Vilon, neuroendocrine status and sexual function in old male rats
- Khavinson et al. (2001): Vilon and digestive enzyme activity in rats